Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 133 of 5804
-
Could a Two-Drug combo outsmart advanced cervical cancer?
Disease control Not yet recruitingThe goal of this observational study is to evaluate the effectiveness and safety of Iparomlimab and Tuvonralimab (QL1706)-based therapy in patients with recurrent or metastatic cervical cancer who have experienced disease progression after platinum-based treatment. The main ques…
Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill combo aims to delay chemo in advanced breast cancer
Disease control Recruiting nowThe purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial u…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Brain scans reveal how Weight-Loss drugs rewire appetite in teens vs adults
Disease control Not yet recruitingGlucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain ci…
Phase: PHASE3 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Radiation and immunotherapy combo shows promise against esophageal cancer
Disease control OngoingThis study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.
Phase: PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Two-Drug sequence aims to clear CLL cells and let patients stop treatment
Disease control Not yet recruitingThe goal of this clinical trial is to learn if zanubrutinib induction followed by delayed fixed-duration combination with sonrotoclax works to treat previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). It will also learn about the safety of th…
Phase: PHASE2 • Sponsor: Yi Shuhua • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo aims to boost cervical cancer survival
Disease control Not yet recruitingThis is a prospective, multi-center, randomized controlled phase II clinical trial aimed at exploring the efficacy evaluation of cadilonilumab immunotherapy combined with chemotherapy for locally advanced cervical cancer.
Phase: PHASE2 • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough prostate cancers: adding chemo to targeted therapy
Disease control Recruiting nowThis is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide and ADT, assessed by event-free survival, in patients with mHSPC who do not achieve deep PSA response (≤0,2 ng/ml or PSA90 response …
Phase: PHASE3 • Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to tame Narcolepsy's sleep attacks and sudden muscle weakness
Disease control Recruiting nowThis is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating excessive daytime sleepiness (EDS), cataplexy, sleepiness/wakefulness, and fatigue in adult participants (ages ≥18 …
Phase: PHASE3 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Drug cocktail aims to stop liver cancer recurrence after surgery
Disease control Recruiting nowStudy to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.
Phase: PHASE2 • Sponsor: Fundacion Clinic per a la Recerca Biomédica • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo aims to tame lupus kidney disease in kids
Disease control Not yet recruitingThe objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Less radiation for breast cancer? a trial tests a smarter, response-based approach
Disease control Not yet recruitingProspective Comparative Study of Response-Adapted De-escalation of Regional Nodal Irradiation in Initially Node Positive Breast Cancer Patients with Pathological Nodal Complete Response After Neoadjuvant Therapy
Phase: NA • Sponsor: Aya Ahmed Sayed • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Video game meets glucose monitor: a new way to teach diabetes skills to children
Disease control Recruiting nowType 1 diabetes diagnosed in childhood requires rapid acquisition of complex self-management skills while children and caregivers are also adapting emotionally and socially to a chronic condition. Standard diabetes education is often delivered early after diagnosis, is informatio…
Phase: NA • Sponsor: Shifa International Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo therapy aims to boost remission in tough rectal cancer
Disease control Not yet recruitingThis study aims to observe and evaluate the efficacy and safety of moderately hypofractionated radiotherapy combined with chemotherapy and immunotherapy, compared with conventional neoadjuvant chemoradiotherapy, in patients with high-risk locally advanced colorectal cancer.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Lung cancer Patients' own immune cells deployed in new trial
Disease control Not yet recruiting28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.
Phase: PHASE2 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail aims to boost transplant success in tough leukemias
Disease control Not yet recruitingThis study was designed as a prospective, multicenter, open-label, randomized controlled trial. Eligible participants were patients aged 15-65 years with high risk or relapsed/refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic neoplasm…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
Disease control Not yet recruitingThe purpose of this Chinese extension study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could …
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo aims to outperform standard care in aggressive lung cancer
Disease control Not yet recruitingThe objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Phase: PHASE3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo aims to tackle Hard-to-Treat leukemia
Disease control Not yet recruitingThe purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine(VA) induction followed by bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hypoplastic and secondary acute myeloid leukemia (AML).
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Four-Drug cocktail aims to control myeloma without transplant
Disease control Recruiting nowPrimary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in China. And Secondary Objectives is, To assess the MR…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
Disease control Not yet recruitingThis is a prospective, single-arm, open-lable, single-center study and we aimed to determine whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim could induce sustained response off-treatment (SRoT) in adult patients with ITP following CS failure.
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC